4.2 Article

Diagnosis of Alzheimer's Disease Based on Structural MRI Images Using a Regularized Extreme Learning Machine and PCA Features

Journal

JOURNAL OF HEALTHCARE ENGINEERING
Volume 2017, Issue -, Pages -

Publisher

HINDAWI LTD
DOI: 10.1155/2017/5485080

Keywords

-

Funding

  1. National Research Foundation (NRF) - Korean government [NRF-2015R1D1A1A01060422, NRF-2014M3C7A1046050, NRF-2016M3C7A1905477]
  2. MISP (Ministry of Science, ICT AMP
  3. Future Planning), Korea, under the National Program for Excellence in SW
  4. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant) [U01 AG024904]
  5. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  6. National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering
  7. AbbVie, Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica Inc.
  11. Biogen
  12. Bristol-Myers Squibb Company
  13. CereSpir Inc.
  14. Cogstate
  15. Eisai Inc.
  16. Elan Pharmaceuticals Inc.
  17. Eli Lilly and Company
  18. EuroImmun
  19. F. Hoffmann-La Roche Ltd.
  20. Genentech Inc.
  21. Fujirebio
  22. GE Healthcare
  23. IXICO Ltd.
  24. Janssen Alzheimer Immunotherapy Research AMP
  25. Development LLC
  26. Johnson AMP
  27. Johnson Pharmaceutical Research AMP
  28. Development LLC
  29. Lumosity
  30. Lundbeck
  31. Merck Co. Inc.
  32. Meso Scale Diagnostics LLC
  33. NeuroRx Research
  34. Neurotrack Technologies
  35. Novartis Pharmaceuticals Corporation
  36. Pfizer Inc.
  37. Piramal Imaging
  38. Servier
  39. Takeda Pharmaceutical Company
  40. Transition Therapeutics
  41. The Canadian Institutes of Health Research
  42. National Research Foundation of Korea [2015R1D1A1A01060422, 2016M3C7A1905477, 2014M3C7A1046050] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Alzheimer's disease (AD) is a progressive, neurodegenerative brain disorder that attacks neurotransmitters, brain cells, and nerves, affecting brain functions, memory, and behaviors and then finally causing dementia on elderly people. Despite its significance, there is currently no cure for it. However, there are medicines available on prescription that can help delay the progress of the condition. Thus, early diagnosis of AD is essential for patient care and relevant researches. Major challenges in proper diagnosis of AD using existing classification schemes are the availability of a smaller number of training samples and the larger number of possible feature representations. In this paper, we present and compare AD diagnosis approaches using structural magnetic resonance (sMR) images to discriminate AD, mild cognitive impairment (MCI), and healthy control (HC) subjects using a support vector machine (SVM), an import vector machine (IVM), and a regularized extreme learning machine (RELM). The greedy score-based feature selection technique is employed to select important feature vectors. In addition, a kernel-based discriminative approach is adopted to deal with complex data distributions. We compare the performance of these classifiers for volumetric sMR image data from Alzheimer's disease neuroimaging initiative (ADNI) datasets. Experiments on the ADNI datasets showed that RELM with the feature selection approach can significantly improve classification accuracy of AD from MCI and HC subjects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available